[go: up one dir, main page]

NO20056028L - Anvendelse av SIP - Google Patents

Anvendelse av SIP

Info

Publication number
NO20056028L
NO20056028L NO20056028A NO20056028A NO20056028L NO 20056028 L NO20056028 L NO 20056028L NO 20056028 A NO20056028 A NO 20056028A NO 20056028 A NO20056028 A NO 20056028A NO 20056028 L NO20056028 L NO 20056028L
Authority
NO
Norway
Prior art keywords
compound
activity
samples
receptor
derivative
Prior art date
Application number
NO20056028A
Other languages
English (en)
Inventor
Martin Michaelis
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20056028L publication Critical patent/NO20056028L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anvendelse av SIP eller fimksjonelle fragmenter eller derivater av den for tillagingen av farmasøytiske forbindelser.
NO20056028A 2003-05-30 2005-12-19 Anvendelse av SIP NO20056028L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20030012389 EP1481680A1 (en) 2003-05-30 2003-05-30 Use of S1P
PCT/EP2004/005236 WO2004105773A2 (en) 2003-05-30 2004-05-15 Use of s1p

Publications (1)

Publication Number Publication Date
NO20056028L true NO20056028L (no) 2006-02-27

Family

ID=33104118

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056028A NO20056028L (no) 2003-05-30 2005-12-19 Anvendelse av SIP

Country Status (14)

Country Link
US (2) US7691563B2 (no)
EP (2) EP1481680A1 (no)
JP (2) JP4843492B2 (no)
KR (1) KR101169916B1 (no)
CN (1) CN1838961B (no)
AT (1) ATE532522T1 (no)
AU (2) AU2004243475C1 (no)
BR (1) BRPI0410960A (no)
CA (2) CA2527759C (no)
DK (1) DK1641468T3 (no)
IL (1) IL172203A (no)
NO (1) NO20056028L (no)
RU (1) RU2362565C2 (no)
WO (1) WO2004105773A2 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
US7638637B2 (en) * 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
EP1863463A1 (en) 2005-02-14 2007-12-12 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substitued by amino and phenyl groups
AU2007209961A1 (en) * 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
WO2007092638A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
AU2007323540A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007323618A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
CA2669124A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
WO2009053481A1 (en) * 2007-10-25 2009-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for modulating nk and t cell trafficking
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
EP2769724A1 (en) * 2013-02-22 2014-08-27 Université d'Aix-Marseille Inhibitors of Na(v) 1.9 channel activity and uses thereof for treating pain
JP6450315B2 (ja) * 2013-08-20 2019-01-09 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｓ１ｐ１受容体アゴニストの評価方法及びスクリーニング方法
SG11202006528XA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
SG11202006526YA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN113350363B (zh) * 2021-06-30 2022-02-22 中国矿业大学(北京) N-棕榈酰-d-鞘磷脂在制备预防和/或治疗神经性疼痛的药物中的应用
CN113444727B (zh) * 2021-06-30 2022-06-21 中国热带农业科学院热带生物技术研究所 一种LncRNA及其应用
CN117024564A (zh) * 2021-11-17 2023-11-10 罗赣 一种多肽改造体及其在制备抗炎杀菌药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260288A (en) * 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5712262A (en) * 1996-11-21 1998-01-27 Spiegel; Sarah Use of sphingosine-1-phosphate to suppress programmed cell death
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
DE19810999A1 (de) * 1998-03-13 1999-09-16 Dermapharm Gmbh Verwendung von Sphingosin, Sphingosin-1-Phosphat, Sphingosin-1-Phosphat-Derivaten und/oder deren Gemischen zur Behandlung von entzündlichen Hautkrankheiten
ES2151828B1 (es) * 1998-07-10 2001-08-16 Esteve Labor Dr Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor.
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2001278750A (ja) * 2000-03-29 2001-10-10 Hideoki Ogawa 新規育毛剤
JP2004529100A (ja) * 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト

Also Published As

Publication number Publication date
CA2809131A1 (en) 2004-12-09
RU2362565C2 (ru) 2009-07-27
WO2004105773A3 (en) 2006-04-27
AU2004243475B2 (en) 2010-08-12
AU2004243475A1 (en) 2004-12-09
AU2004243475C1 (en) 2011-01-20
US7691563B2 (en) 2010-04-06
KR20060054188A (ko) 2006-05-22
KR101169916B1 (ko) 2012-08-06
RU2005137176A (ru) 2006-06-10
EP1641468B1 (en) 2011-11-09
US9271992B2 (en) 2016-03-01
EP1481680A1 (en) 2004-12-01
CA2527759C (en) 2014-04-15
JP2007518698A (ja) 2007-07-12
CN1838961A (zh) 2006-09-27
AU2010235846B2 (en) 2012-10-18
US20100137257A1 (en) 2010-06-03
US20050032744A1 (en) 2005-02-10
IL172203A (en) 2012-09-24
JP4843492B2 (ja) 2011-12-21
JP5460627B2 (ja) 2014-04-02
WO2004105773A2 (en) 2004-12-09
JP2011168589A (ja) 2011-09-01
AU2010235846A1 (en) 2010-11-04
BRPI0410960A (pt) 2006-07-04
DK1641468T3 (da) 2012-02-27
EP1641468A2 (en) 2006-04-05
IL172203A0 (en) 2006-04-10
CA2527759A1 (en) 2004-12-09
ATE532522T1 (de) 2011-11-15
CN1838961B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
NO20056028L (no) Anvendelse av SIP
Weinbrenner et al. Remote preconditioning by infrarenal aortic occlusion is operative via δ1-opioid receptors and free radicals in vivo in the rat heart
Yamamoto et al. Antinociceptive effects of N‐acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ‐11, ZJ‐17 and ZJ‐43 in the rat formalin test and in the rat neuropathic pain model
Neale et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family
Martina et al. The sigma‐1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus
Sugiuar et al. TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation
Wang et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain
Sajikumar et al. Synaptic tagging and cross-tagging: the role of protein kinase Mζ in maintaining long-term potentiation but not long-term depression
Tabernero et al. Glucose metabolism and proliferation in glia: role of astrocytic gap junctions
Gupta et al. Potentiation of μ‐opioid receptor‐mediated signaling by ketamine
Luo et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats
Melemedjian et al. mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK
Molinari et al. [Dmt1] N/OFQ (1–13)‐NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist
Koetzner et al. Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and-2
Schneider et al. Opioid-activated postsynaptic, inward rectifying potassium currents in whole cell recordings in substantia gelatinosa neurons
Zsombok et al. Sympathetic circuits regulating hepatic glucose metabolism: where we stand
Zhou et al. The glutamatergic nature of TRPV1‐expressing neurons in the spinal dorsal horn
Vieyra-Reyes et al. Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression
Gavioli et al. Central injections of nocistatin or its C‐terminal hexapeptide exert anxiogenic‐like effect on behaviour of mice in the plus‐maze test
Farrag et al. Endomorphins potentiate acid‐sensing ion channel currents and enhance the lactic acid‐mediated increase in arterial blood pressure: Effects amplified in hindlimb ischaemia
Qiu et al. MicroRNA‐7 inhibits melatonin synthesis by acting as a linking molecule between leptin and norepinephrine signaling pathways in pig pineal gland
Smith et al. Leptin influences the excitability of area postrema neurons
Barak et al. Glial cell line‐derived neurotrophic factor (GDNF) is an endogenous protector in the mesolimbic system against excessive alcohol consumption and relapse
Barea-Rodrıguez et al. Protein synthesis inhibition blocks the induction of mossy fiber long-term potentiation in vivo
Ghetti et al. NMDA-dependent modulation of hippocampal kainate receptors by calcineurin and Ca2+/calmodulin-dependent protein kinase